SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer

被引：2

作者：

Oliveira, M. ^{[1
]}

Cejalvo Andujar, J. M. ^{[2
]}

Margeli Vila, M. ^{[3
]}

Tolosa Ortega, P. ^{[4
]}

Martinez Saez, O. ^{[5
]}

Salvador Bofill, F. J. ^{[6
]}

Cruz Jurado, J. ^{[7
]}

Barrera, A. M. Luna ^{[8
]}

Arumi De Dios, M. A. ^{[9
]}

Vidal Losada, M. J. ^{[10
]}

Guerra, J. A. ^{[11
]}

Pernas Simon, S. ^{[12
]}

Villacampa Javierre, G. ^{[13
]}

Gonzalez-Farre, B. ^{[14
]}

Sanfeliu Torres, E. ^{[14
]}

Santhanagopal, A. ^{[15
]}

Falato, C. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[17
]}

Prat, A. ^{[18
]}

机构：

[1] Vall Hebron Univ Hosp, Med Oncol Dept, SOLTI, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, SOLTI, Badalona, Spain

[4] Hosp Univ 12 Octubre, SOLTI, Oncol Dept, Valencia, Spain

[5] Hosp Clin Barcelona, SOLTI, Dept Med Oncol, Barcelona, Spain

[6] Hosp Univ Virgen Valme, Med Oncol Dept, Seville, Spain

[7] Hosp Univ Canarias, Med Oncol Dept, Santa Cruz De Tenerife, Canary Islands, Spain

[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[9] Univ Barcelona, Fac Med, Med Oncol Dept, Barcelona, Spain

[10] Hosp Clin Barcelona, SOLTI, Med Oncol Dept, Barcelona, Spain

[11] Hosp Univ Fuenlabrada, Med Oncol Dept, Fuenlabrada, Spain

[12] Hosp Duran i Reynals, Med Oncol Breast Unit, SOLTI, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[13] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Stat Dept, SOLTI, Barcelona, Spain

[14] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[15] Daiichi Sankyo Inc, Res & Dev, Basking Ridge, NJ USA

[16] IDIBAPS August Pi i Sunyer Biomed Res Inst, Translat Genom & Targeted Therapies, Barcelona, Spain

[17] SOLTI HQ, Clin Res Dept, Barcelona, Spain

[18] Hosp Clin Barcelona, IDIBAPS, SOLTI, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

202TiP

引用

页码：S628 / S628

页数：1

共 50 条

[41] The SURVIVE-HERoes trial - a secondary adjuvant treatment intervention study with trastuzumab-deruxtecan in early breast cancer patients with HER2 positive/HER2 low tumors and a molecular relapse based on a ctDNA-liquid biopsy approach
Mergel, Franziska
Huesmann, Sophia
Pfister, Kerstin
Fink, Angelina
Schaeffler, Henning
Mehmeti, Forca
Fehm, Tanja
Mueller, Volkmar
Pantel, Klaus
Friedl, Thomas W. P.
Wiesmueller, Lisa
Erber, Ramona
Hartmann, Arndt
Beckmann, Matthias
Fasching, Peter Andreas
Hartkopf, Andreas
Rack, Brigitte
Janni, Wolfgang
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 34 - 35
[42] Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2-and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial
Costa, Ricardo L.
Childress, Jennifer A.
Abraham, Edith
Farrell, Carly
Mo, Qianxing
Jameel, Zena
Muller, Aixa Elena Soyano
Lee, Kimberley T.
Hoover, Susan
Kiluk, John
Weinfurtner, Robert J.
Lee, Marie Catherine
Laronga, Christine
Khakpour, Nazanin
Han, Hyo S.
Khong, Hung T.
Soliman, Hatem Hussein
Czerniecki, Brian J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
Martin, M.
Holmes, F. A.
Moy, B.
Mansi, J.
Gnant, M.
Buyse, M.
Barrios, C.
Bryce, R.
Wong, A.
Chan, A.
BREAST, 2021, 56 : S19 - S19
[44] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
Modi, Shanu
Jacot, William
Yamashita, Toshinari
Sohn, Joohyuk
Vidal, Maria
Tokunaga, Eriko
Tsurutani, Junji
Ueno, Naoto T.
Chae, Yee Soo
Lee, Keun Seok
Niikura, Naoki
Park, Yeon Hee
Wang, Xiaojia
Xu, Binghe
Gambhire, Dhiraj
Yung, Lotus
Meinhardt, Gerold
Wang, Yibin
Harbeck, Nadia
Cameron, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[45] Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+metastatic breast cancer.
Stewart, JA
Fehrenbacher, L
Blanchard, RA
Rodriguez, GI
Vogel, CL
Anavekar, P
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 78S - 78S
[46] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Fehm, Tanja
Cottone, Francesco
Dunton, Kyle
Andre, Fabrice
Krop, Ian
Park, Yeon Hee
De laurentiis, Michelino
Miyoshi, Yasuo
Armstrong, Anne
Borrego, Manuel Ruiz
Yerushalmi, Rinat
Duhoux, Francois P.
Takano, Toshimi
Lu, Wenjing
Egorov, Anton
Kim, Sung-Bae
LANCET ONCOLOGY, 2024, 25 (05): : 614 - 625
[47] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02)
Andre, Fabrice
Shahidi, Javad
Lee, Caleb
Wang, Kongming
Krop, Ian E.
CANCER RESEARCH, 2020, 80 (04)
[48] Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial
Holmes, Frankie Ann
Moy, Beverly
Delaloge, Suzette
Chia, Stephen
Ejlertsen, Bent
Mansi, Janine
Iwata, Hiroji
Gnant, Michael
Buyse, Mark
Barrios, Carlos
Silovski, Tajana
Separovic, Robert
Bashford, Anna
Guerrero-Zotano, Angel
Denduluri, Neelima
Patt, Debra
Gokmen, Erhan
Gore, Ira
Smith, John
Bryce, Richard
Xu, Feng
Wong, Alvin
Martin, Miguel
Chan, Arlene
CANCER RESEARCH, 2021, 81 (04)
[49] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 5 - 6
[50] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 17

← 1 2 3 4 5 →